RxDoctor Payments DataLook up a doctor →

R White, MD

Pulmonary Disease · Rochester, NYNPI 1366477044

Payments from drug & device makers

$3,054,967in general payments, 2019–2025

Across 415 payments — averaging $7361.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$2.5M
  • United Therapeutics Corporation$426K
  • Janssen Research & Development, LLC$131K
  • Bayer$42K
  • Sandoz$247
  • Actelion Pharmaceuticals US, Inc.$191
  • plus $86 from 1 others
$1,851in research payments, 2019–2025

Across 5 payments — averaging $370.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • United Therapeutics Corporation$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,054,967 in reported general payments places this provider in the 95th percentile of 1,115 pulmonary disease providers in New York.

See all pulmonary disease providers in New York

Medicare billing

Part B allowed, 2024
$25,000
Medicare patients
121
Services billed
263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →